Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | arachidonate 5-lipoxygenase-activating protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | Protein kinase C, brain isozyme | 0.0088 | 0.3952 | 0.513 |
Toxoplasma gondii | MAPEG family protein | 0.0135 | 0.7704 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.7801 | 0.7801 |
Loa Loa (eye worm) | hypothetical protein | 0.0156 | 0.9356 | 0.9356 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0088 | 0.3952 | 0.4694 |
Echinococcus granulosus | protein kinase c epsilon type | 0.0118 | 0.6292 | 0.8168 |
Brugia malayi | protein kinase C II. | 0.0118 | 0.6292 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase N2 | 0.0096 | 0.4539 | 0.5892 |
Echinococcus multilocularis | microsomal glutathione S transferase 3 | 0.0135 | 0.7704 | 1 |
Entamoeba histolytica | PH domain containing protein kinase, putative | 0.0069 | 0.2388 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.7801 | 0.7801 |
Schistosoma mansoni | microsomal glutathione s-transferase | 0.0135 | 0.7704 | 1 |
Echinococcus granulosus | microsomal glutathione S transferase 3 | 0.0135 | 0.7704 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0136 | 0.7801 | 0.7801 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0118 | 0.6292 | 0.8004 |
Schistosoma mansoni | membrane associated proteins in eicosanoid and glutathione metabolism family member | 0.0135 | 0.7704 | 1 |
Echinococcus granulosus | protein kinase c iota type | 0.0047 | 0.0633 | 0.0821 |
Echinococcus multilocularis | serine threonine protein kinase | 0.0069 | 0.2397 | 0.3112 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0088 | 0.3952 | 0.4694 |
Echinococcus multilocularis | protein kinase c epsilon type | 0.0118 | 0.6292 | 0.8168 |
Echinococcus multilocularis | protein kinase c iota type | 0.0047 | 0.0633 | 0.0821 |
Loa Loa (eye worm) | AGC/PKC/ALPHA protein kinase | 0.0042 | 0.0246 | 0.0246 |
Echinococcus granulosus | protein kinase C gamma type | 0.0069 | 0.2397 | 0.3112 |
Loa Loa (eye worm) | AGC/PKC/ETA protein kinase | 0.0118 | 0.6292 | 0.6292 |
Echinococcus granulosus | Protein kinase C brain isozyme | 0.0088 | 0.3952 | 0.513 |
Onchocerca volvulus | 0.0136 | 0.7801 | 0.5 | |
Echinococcus granulosus | serine:threonine protein kinase N2 | 0.0069 | 0.2388 | 0.31 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.1555 | 0.1555 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 593.2 nM | BindingDB_Patents: Homogeneous Time Resolved Fluorescence Assay. The assay below is used to test the modulatory activity of compounds against FLAP. Human and mouse FLAP-encoding DNA was amplified by polymerase chain reaction and cloned into pFastBac1 (Invitrogen) with a NH2-terminal 6-His tag for expression in Spodoptera frugiperda (Sf-9) cells. FLAP-containing membranes were prepared as was a FITC-labeled FLAP modulator (3-(3-(tert-butylthio)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl)-2,2-dimethylpropanoic acid). The FLAP binding assay is performed in HTRF format (homogeneous time resolved fluorescence). FLAP-containing membranes (1 ug/well final for human) are incubated in the presence of the HTRF ligand, [5-[({[2-(2-{3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(quinolin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropanoyl}hydrazino)-2-oxoethyl]sulfanyl}acetyl)amino]-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid] (25 nM final), a terbium labeled anti-His tag antibody (0.5 ng/well final, from Cisbio) and compounds. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.